CytoMed Therapeutics (GDTC) said Monday it has signed a five-year business and research collaboration deal with SunAct Cancer Institute.
The companies plan to explore the efficacy, potency, safety, and tolerability of CytoMed's proprietary allogeneic gamma delta T cells to treat different cancers in human subjects through clinical research, CytoMed said.
The joint effort will include a phase 2 investigator-initiated trial in India that will be jointly sponsored by the two companies, CytoMed said.
CytoMed shares were up over 22% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。